Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"SGLT2-inhibitor"”.
-
Comparing Healthcare Resource Utilization and Costs in HFPEF patients using SGLT2-inhibitor Combination Treatments: A Retrospective Claims Analysis
… recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) as foundational therapy, with the addition of either mineralocorticoid receptor antagonists (MRAs) or angiotensin receptor-neprilysin inhibitors (ARNIs) as adjunctive therapy. However, real-world evidence comparing healthcare …
-
EFFECTS OF DAPAGLIFLOZIN ON EXERCISE CAPACITY, RESPIRATORY FUNCTION, BIOMARKERS, SLEEP APNEA, AND LEFT VENTRICULAR REMODELING IN PATIENTS WITH HEART FAILURE: A PROSPECTIVE, SINGLE CENTER, NON RANDOMIZED STUDY
… Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has become a cornerstone in the management of heart failure with reduced ejection fraction (HFrEF). Its clinical efficacy is well-established, primarily attributed to its effects on diuresis and hemodynamic unloading. However, …
-
A Comprehensive Analysis of SGLT2-inhibition in Type 2 Diabetes and Heart Failure
… The sodium-glucose linked co-transporter type 2 (SGLT2)-inhibitor class of drug was developed as a novel anti-diabetic agent that acts independent of the insulin-incretin pathway to lower blood sugar. Part of the off-target effects that have been seen with this drug class include weight loss, …
-
Effects of Chronic High Sucrose With Dietary or Drinking Inclusion on the Electrogenic Glucose Absorption in the Intestinal Tract of Mice (Mus musculus)
… differences in inhibition by dapagliflozin, an SGLT2 inhibitor or phloridzin dihydrate, an SGLT1 inhibitor were evident, gene expression analysis of the SGLT 1- 6 could not fully explain these regional differences in kinetics. Non-the-less, the kinetics were highly modified by sucrose …
-
Epicardial Adipose Tissue: Relationship with Cardiovascular Disease and the Effect of Therapeutic Interventions
… for 12 months and in REFORM Study in which an SGLT2 inhibitor, dapagliflozin, was given to patients with T2DM and heart failure for 12 months, the impact of these two drugs on EAT area were examined by measuring the EAT area pre and post intervention. <br/><br/>Results <br/>In SUMMIT study, EAT …